HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Alessandro Parolari Paolo Biglioli Francesco Alamanni Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Parolari, A. Articles by Alamanni, F. Search for Related Content PubMed Articles by Parolari, A. Articles by Alamanni, F. Related Collections Valve disease

Review

Nonrheumatic calcific aortic stenosis: an overview from basic science to pharmacological prevention

^a Department of Cardiac Surgery, Unit for Clinical Research in Atherothrombosis, Centro Cardiologico Monzino IRCCS, University of Milan, Milan, Italy
^b Department of Pharmacological Sciences, University of Milan, Milan, Italy

Received 5 October 2008; received in revised form 18 November 2008; accepted 26 November 2008.

^_* Corresponding author. Address: Department of Cardiac Surgery – University of Milan, Centro Cardiologico – Fondazione Monzino IRCCS, Via Parea, 4, 20138, Milan, Italy. Tel.: +39 02 580021; fax: +39 02 58011194. (Email: alessandro.parolari{at}cardiologicomonzino.it).

Calcific aortic stenosis is a frequent degenerative disease, which represents the most common indication for adult heart valve surgery, and carries substantial morbidity and mortality. Due to ageing populations in western countries, its prevalence is expected to increase in the coming years. Basic science studies suggest that the progression of aortic valve stenosis involves an active biological process, and that the molecular mechanisms promoting this development resemble those of atherosclerosis, as stenotic aortic valves are characterized by complex histological lesions, consisting of activated inflammatory cells, lipid deposits, extracellular matrix remodeling, calcific nodules, and bone tissue. This has led to the hypothesis that drugs effective in delaying atherosclerosis progression (e.g. statins) might also be able to prevent the progression of calcific aortic valve stenosis. The potential benefit of statin therapy, however, is controversial and widely debated, as recent randomized studies done in patients with moderate to severe degrees of aortic stenosis failed to consistently show substantial benefits of this class of drugs. This review focuses on various aspects of molecular mechanisms underlying calcific aortic valve stenosis and discusses recent experimental and clinical studies that address the potential benefit of targeted drug therapies. Taken together, current evidence suggests that the progression of calcific aortic stenosis is a multi-factorial process; the multitude of the mechanisms potentially involved in aortic valve stenosis indicates that drug therapy aimed at reducing its progression is necessarily multi-factorial and should address the earliest stages of the disease, as it is now evident that pharmacological treatment administered in more advanced stages of the disease may be ineffective or, at best, much less effective.

Key Words: Calcific aortic valve stenosis • Atherosclerosis • Statins